Congressional inquiry into Alzheimer's drug faults Biogen and FDA
The report said the FDA's approval process for Aduhelm was "rife with irregularities" and criticized Biogen for setting an "unjustifiably high price." The post Congressional inquir…
More from Greater Boston
The Boston Hockey Blog
INSTANT TAKEAWAYS: Terriers suffer first loss of the season in 2-1 defeat against Vermon
Greater Boston
•
7h ago
The Somerville TImes
Fire in Somerville caused by battery-powered skateboard
Greater Boston
•
10h ago
